SLC5A2 and chronic kidney disease: Inhibitors of the sodium-glucose cotransporter 2 (SGLT2), a new class of antihyperglycemic drugs, has been showed to not only lower the level of glucose, but also improve renal and cardiovascular outcomes in patients with CKD [24, 25].